Loading clinical trials...

A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients | Clinical Trials | Clareo Health

COMPLETEDPHASE1

A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients

A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients (Single Dose Study)

NCT03570957•Tanabe Pharma Corporation

Summary

The objective of this study is to investigate the safety, tolerability, and pharmacokinetics of MT-2990 in patients with Japanese cedar pollen-induced seasonal allergic rhinitis (JC-SAR). Additional objective of the study is to investigate the efficacy and pharmacodynamics profile of MT-2990 in an environmental exposure chamber (EEC) on Day 8, 29, 57, and 85.

Eligibility

Age

20 - 64 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•A body weight of 40 to 100 kg for female or 45 to 100 kg for male
•A body mass index of 18 to 30 kg/m2
•Subjects who have current history of JC-SAR in previous 2 consecutive years.
•Presence (CAP-RAST: ≥2) of IgE specific to Japanese cedar pollens and absence (CAP-RAST: ≤1) of IgE specific to other 4 allergens
•Presence of at least 2 symptoms, which are moderate to very severe, in 4 nasal symptoms (runny nose, sneezing, blocked nose, itchy nose) at any time point during allergen exposure in EEC at screening period

Exclusion Criteria

•Presence of any symptoms of allergic rhinitis within 1 year except scattering season of cedar pollen or cypress pollen
•Subjects who have persistent symptom caused by allergen exposure in EEC at screening period until Day 1 (pre-dose)
•Underwent nasal surgery (include laser surgery) to improve nasal symptoms within 2 years
•Underwent specific immunotherapy or non-specific immunotherapy within 5 years
•Underwent medication of anti-histamine, oral mast cell stabilizer, leukotriene receptor antagonist, prostaglandin D2/thromboxane A2 receptor antagonist, Th2 cytokine inhibitor, corticosteroid (oral form, intra-nasal form, ocular form), or vasoconstrictor within 4 weeks
•Underwent medication of corticosteroid (injection form) or anti-IgE antibody within 6 months
•Subject who is concerned about exacerbation of the physical condition due to allergen exposure in EEC

Locations (1)

Investigational Site

Tokyo, Japan

Key Dates

Start Date

July 17, 2018

Primary Completion Date

December 27, 2018

Completion Date

December 27, 2018

Last Updated

December 11, 2025

Enrollment

ACTUAL participants

Conditions

Seasonal Allergic Rhinitis

Interventions

MT-2990

DRUG

Placebo

DRUG

A Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis

NCT06837233

Seasonal Allergic Rhinitis

View study

COMPLETEDPHASE3

Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen

NCT05540717

Seasonal Allergic RhinitisRhinoconjunctivitis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 11, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients

Inclusion Criteria

Exclusion Criteria

A Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis

Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen

Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Seasonal Allergic Rhinitis (MK-4117-204)

To Investigate Drug-drug Interaction and Relative Bioavailability Between the FDC AzelastineHCL/Beclomethasone Dipropionate Nasal Spray, & Beclomethasone Dipropionate Nasal Spray in the Test Vehicle, and RinoClenil® Nasal Spray

Efficacy and Safety of Azelastine +Mometasone , Nasal Spray, 140 mcg + 50 mcg, (Sandoz d.d., Slovenia) and Momat Rino Advance, Nasal Spray, 140 mcg + 50 mcg, (Glenmark, India) Administered as a Monotherapy to Patients With Seasonal Allergic Rhinitis.

To Study GSP 301 in Patients With Seasonal Allergic Rhinitis